Pfizer and BioNTech have released the results of their Phase III clinical trial which shows 100 percent effectiveness for those aged 12 to 15. The vaccine was already Medsafe-approved for those aged 16 years and above. According to the Ministry of Health, Medsafe is expected to be provided the data on the mentioned clinical trial in due course.

In New Zealand, more than 1 million people or 20 percent of the population are under 16 years old and it is important to vaccinate young people to achieve herd immunity.

However, New Zealand may not be at the front queue as it is more likely that they will prioritize countries with higher Covid-19 cases, a spokesperson of the Ministry of Health said. "Medsafe will need to review the data to consider approving an extension," the ministry spokesperson said, adding that thorough security and adequacy guidelines would need to be met.

The trial showed a strong antibody response and tolerable side effects consistent with those seen in adults aged 16 to 25. It included 2260 adolescents in the United States, with and without evidence of prior SARS-CoV-2 (the virus that causes the disease) infection. There were 18 cases of Covid-19 in the placebo group and none in the vaccinated group.

A strong antibody reaction was seen in a subset of young people one month after the second dose. Further clinical trials have commenced in children aged 5 to 11 and are expected to begin in younger children aged 2 to 5 in early April, followed by ages six months to 2 years old.

Covid-19 Response Minister Chris Hipkins said the Government has ordered enough stock to administer the vaccine across all age groups in the country.

"Hopefully, with data looking this promising, we will not be too far away from being able to broaden our New Zealand Covid-19 immunization program to children as well.

"In doing so we will ensure more New Zealanders are protected individually and also, with more New Zealanders vaccinated, the more we will be in a position to reduce the risk of community spread."

"In the event that they don't [get approved], we've got our bases covered because of the broad portfolio that we've got. For example, the AstraZeneca could prove to be the right vaccine for younger New Zealanders, or Novavax [or Janssen]."


Sputnik-V rollout in Delhi, Postponed Once Again!

Treatment Using Genetic Engineering and Light-Activated Therapy has Helped a Blind Man Regain Partial Sight in One Eye

Sanofi S.A. has Agreed to a Pensions Package of Approximately £770 million ($1.1 billion)

French CDMO Yposkesi to Build a Second Commercial Cell and Gene Therapy Plant

Unusable Vaccine Doses at Baltimore Plant Investigated by FDA

Danish government needs to reevaluate dropped antibodies

WHO currently utilizing Greek letters in order for Covid variation names

GP Clinics is now ready to accept COVID-19 Vaccinations for ages over 50

EU Signed a Contract with Pfizer for Almost 1.8 Billion Doses of the Coronavirus Vaccine

Pfizer has gauge $26 billion in Covid-19 antibody deals this year

Hospira, Inc Under Investigation After Reported Mislabeling

Global Access to COVID-19 Vaccines

Moderna Is Testing a New Version of Its COVID-19 Vaccine That Wouldn’t Require Ultra-Cold Storage

No Logical Proof COVID-19 Vaccine Affects Menstruation or Fertility

Full Steam Ahead on Johnson & Johnson and AstraZeneca Vaccines

India Established a Record for Daily Infections Worldwide

Vaccines to Detainees at Guantanamo Bay are now being Offered by the U.S.

Israel's Quick and Effective Vaccine Rollout

J&J Pause a Mere Bump in the U.S. Antibody Rollout?

Stoppage in the Utilization of Johnson and Johnson's Covid-19 Vaccine

Supply Constraints Ease in U.S. Vaccine Rollout

Israel's Vaccine Rollout Curbs Covid-19 Spread

Effects of England's salt reduction Program

The COVID-19 Vaccination Race in Asia

UK and the EU are as yet entangled in an unpleasant disagreement about a deficiency of antibodies across Europe

Progress of COVAX Deliveries

Non-AstraZeneca option for under 30s; E.U. tracks down a 'potential connect' to rare clots

Emergent BioSolutions Threw Out Millions of Doses of Covid-19 Vaccines

Kidney Transplants on the Rise

Vaccine Passports

Coronavirus Briefing: U.S. Economy Bounces Back

India Recorded its Highest Tally of New Coronavirus Infections

Moderna dishes out for CEO security as its COVID-19 immunization gets the spotlight

Netherlands the Latest Country to Prohibit the Use of AstraZeneca Shot

Antibody injections could turn out to be more reasonable with the new production method

NHS study finds that CT scan gets 70% of Lung Cancer at the Beginning Phase

How to Apply DQ/IQ/OQ/PQ in New Framework

Design of an Efficient Stability Programme -Bracketing and Matrixing

QP Declaration

Negotiations on Cost and Availability of New Pharmaceuticals

Covid-19 in China - Statistics & Facts

5 Health Care Stocks to Bet on as Coronavirus Woes Linger

Coronavirus Impact on the Tourism Industry Worldwide

Cold chain distribution; route qualification approaches

The v model in validation

GAMP V computer system validation